# Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)

> **NCT04487886** · PHASE2 · COMPLETED · sponsor: **Emory University** · enrollment: 47 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Duvelisib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04487886
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-18
- **Primary completion:** 2021-06-10
- **Final completion:** 2021-06-10
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2023-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04487886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04487886, "Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04487886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*